Clinical Trials Logo

Psychotic Disorders clinical trials

View clinical trials related to Psychotic Disorders.

Filter by:

NCT ID: NCT03751696 Recruiting - Clinical trials for Common Mental Disorder

Coaching Intervention in Women At-risk of Common Mental Disorders

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

This study aims to provide preventative intervention to 60 women who are at risk of common mental disorders in Hong Kong.

NCT ID: NCT03751488 Completed - Schizophrenia Clinical Trials

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

Start date: December 12, 2018
Phase: Phase 1
Study type: Interventional

This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients

NCT ID: NCT03741751 Recruiting - Clinical trials for Cognitive Impairment

Repetitive TMS & Cognitive Training in Adults With Schizophrenia

CrTMS
Start date: January 15, 2019
Phase: N/A
Study type: Interventional

The proposed project aims to establish the feasibility and tolerability of delivering repetitive transcranial magnetic stimulant (rTMS) combined with computerized cognitive training in patients with Schizophrenia or Schizoaffective Disorder and cognitive difficulties. The investigators will conduct a 2 week randomized controlled trial study evaluating computerized cognitive training combined with either active or sham rTMS on cognitive and functional outcomes in adults with Schizophrenia or Schizoaffective Disorder.

NCT ID: NCT03730831 Recruiting - Schizophrenia Clinical Trials

Narrative Exposure Therapy in Patients With Psychotic Disorders and a Posttraumatic Stress Disorder

NETPSYCH
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Adverse childhood experiences in psychotic disorders are associated with increased cognitive deficits, severe psychotic symptoms, and increased comorbidity. The number of different stress experiences also increases the probability of trauma-associated symptoms. Furthermore, neurobiological changes play a key role in the vulnerability of individuals with early traumas for mental and physical illnesses, among others for diseases of the schizophrenic spectrum disorder and the further course of the disease. The current project pursues a detailed recording of the course of symptoms in inpatients with psychosis to link this data with a systematic recording of childhood experiences and traumatic experiences and biological data. On a subsample of inpatients with psychosis and a comorbid post-traumatic stress disorder (PTSD), the researchers want to investigate whether symptom traits of existing psychotic disorders, biomolecular parameters and cognitive functions can be influenced by a trauma-specific treatment (NET), that has been proven to be effective in the treatment of PTSD.

NCT ID: NCT03729050 Recruiting - Rehabilitation Clinical Trials

Rehabilitation Coordinators in Specialist Psychiatry

Start date: October 24, 2018
Phase: N/A
Study type: Interventional

REKO-A is a randomized controlled intervention study that addressed women and men on sick leave in Uppsala County. Participants which are on sick leave due to mental illness.

NCT ID: NCT03711500 Completed - Schizophrenia Clinical Trials

D-serine Augmentation of Neuroplasticity

Start date: March 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning. D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the optimal dose of D-serine treatment over three sessions of a program designed to measure auditory plasticity.

NCT ID: NCT03708341 Recruiting - Sleep Deprivation Clinical Trials

Exogenous Melatonin in Intensive Care Unit Chronodisruption

EMIC
Start date: November 15, 2018
Phase: Phase 3
Study type: Interventional

To this day, a small number of studies have evaluated the effect of melatonin on the modifications of the characteristics of sleep in critical care units, with mostly a small studied population. However, no study has been realized on a large population, nor has it evaluated the association between genetic factors and response to treatment (melatonin), hence the originality of our study. In our study we hypothesized that systematic melatonin usage in ICU can ameliorate the total sleep time and the fragmentation index and can decrease the confusion related to sleep deprivation.

NCT ID: NCT03708315 Recruiting - Schizophrenia Clinical Trials

BXCL501 for Agitation in Schizophrenia

DEX
Start date: March 9, 2020
Phase: Phase 2
Study type: Interventional

Agitation is characterized by excessive motor or verbal activity, irritability, uncooperativeness, threatening gestures, and, in some cases, aggressive or violent behavior. While agitation may have various underlying causes, patients with schizophrenia are especially vulnerable to acute episodes of agitation, especially during exacerbation of disease, and clinicians do not always diagnose these episodes early enough. Agitation associated with psychosis is a frequent reason for emergency department visits, and unless it is recognized early and managed effectively, it can rapidly escalate to potentially dangerous behaviors, including physical violence. Educating psychiatric professionals about the timely and accurate diagnosis of agitation among patients with schizophrenia or bipolar disorder and developing a well-tolerated easily administered medication will contribute to the prompt and effective management of this condition and could help reduce the risk of violent behavior and other undesirable outcomes. This study is designed to identify the ideal dose range and tolerability of sublingual Dexmedetomidine in patients with schizophrenia.

NCT ID: NCT03705143 Completed - Clinical trials for Substance-Related Disorders

Behavioral Activation for Heroin Use in China: A Randomized Controlled Trial

Start date: June 4, 2018
Phase: N/A
Study type: Interventional

This was a single-site two-arm parallel-group trial conducted in a Methadone Maintenance Treatment (MMT) Clinic that provides medication service for 254 heroin users in Wuhan, China. Once consented and completed the pre-treatment assessment, participants were randomized to receive either the Chinese translated behavioral activation treatment for substance use (C-BA) or treatment as usual (TAU). Research assessments occurred at pre-treatment, post-treatment, and 1- and 3-months follow-ups. The primary purpose of this study is to: 1. Evaluate the feasibility, acceptability, and efficacy of the Chinese-translated behavioral activation treatment for substance use (C-BA), an evidence based intervention developed to address the individual and psychological needs of Chinese substance users. The secondary purpose of this study is to: Examine the underlying mechanism of C-BA by studying the relationship between change in substance use related outcomes and associated psychological constructs (e.g. levels of behavioral activation and depression).

NCT ID: NCT03704805 Completed - HIV Infections Clinical Trials

Effect of a Psychological Intervention on Antiretroviral Therapy and Mental Health Outcomes in HIV-positive Adults in Zimbabwe

Start date: October 5, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to examine the effect of a psychological intervention on antiretroviral therapy outcomes and symptoms of common mental health disorders among adults living with HIV and common mental disorders in rural Zimbabwe.